Kyverna Therapeutics, Inc. (NasdaqGS: KYTX)
Health Care · Biotechnology · US
$6.21
-2.82% today · -10.4% 1Y
Kyverna Therapeutics, Inc. (NasdaqGS: KYTX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $384.05M and employs 149 people.
Over the last twelve months the share price has lost 10.4%, trading between 5.30 and 13.67.
Tweenvest scores Kyverna Therapeutics, Inc. across four factors: quality 35/100, value 56/100. Its strongest factor is value.
KYTX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $384.05M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.88
- Dividend yield
- —
- Beta (5Y)
- 2.07
- 52-week high
- $13.67
- 52-week low
- $5.30
- Avg volume (3M)
- —
- Shares outstanding
- 61.84M
- Employees
- 149
- Next earnings
- —
About Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
- ISIN
- US5019761049
- Founded
- 2018
- Listed since
- Feb 9, 2024
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc.NasdaqGM: ARCT | $390.53M | $12.61 | -8.22% |
| vTv Therapeutics Inc.NasdaqCM: VTVT | $387.40M | $30.46 | -2.31% |
| Opus Genetics, Inc.NasdaqCM: IRD | $386.03M | $4.64 | -0.22% |
| Formycon AGXTRA: FYB | $384.18M | €19.46 | +2.10% |
| Zura Bio LimitedNasdaqCM: ZURA | $383.32M | $4.00 | 0.00% |
| Heartseed Inc.TSE: 219A | $381.84M | ¥2,641.00 | +2.40% |
| Beijing Luzhu Biotechnology Co., Ltd.SEHK: 2480 | $380.46M | HK$15.01 | +12.01% |
| AbClon Inc.KOSDAQ: A174900 | $379.19M | ₩25,550.00 | -8.42% |
Figures last refreshed Oct 11, 2026.